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TNFαWe studied the regulation of RANKL expression inmyeloma by promoter DNAmethylation. Methylation-speciﬁc
polymerase chain reaction showed complete methylation of RANKL promoter inWL-2myeloma cells but partial
methylation in eight other lines. 5-AzadC treatment of WL-2 cells led to demethylation and re-expression of
RANKL. Transwell and contact co-culture ofWL-2 cells with normal bonemarrow-derivedmesenchymal stromal
cells (BMSCs) resulted in comparable repression of DNA methyltransferase-1 (DNMT1) and re-expression of
RANKL in WL-2 cells. Moreover, treatment of WL-2 cells with TNFα led to repression of DNMT1 and re-
expression of RANKL in association with upregulation of miR-140-3p and miR-126, which are partially offset
by addition of anti-TNFα antibody to transwell-coculture ofWL2with BMSC. Taken together, our results showed
that TNFα in the marrow microenvironment led to RANKL demethylation and re-expression in myeloma cells
through DNMT1 repression and upregulation of miR-126-3p and miR-140, both known to repress DNMT1
translation.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Multiple myeloma (MM) is characterized by clonal proliferation of
malignant plasma cells in the bone marrow, associated with osteolytic
bone lesions. Previous studies showed that the receptor for activation
of the nuclear factor-κB ligand (RANKL) is essential for inducing osteo-
clast differentiation and activity [1]. Moreover, clinical studies have
shown that RANKL level was signiﬁcantly increased in the serum and
bone marrow (BM) plasma of MM patients [2,3]. Early studies sug-
gested that RANKL is principally expressed by bone marrowmesenchy-
mal stromal cells (BMSCs) and osteoblasts. However, recent studies
indicated that RANKL could be secreted by myeloma cells, and RANKL
secreted by myeloma cells could induce osteoclast formation, similar
to RANKL derived from BMSCs or osteoblasts [4,5]. Furthermore,
RANKL expression level in myeloma cells is signiﬁcantly correlated
with the extent of osteolytic myeloma bone disease [3,6,7]. Therefore,
RANKL in the BM microenvironment plays a pivotal role in osteolytic
myeloma bone disease.tor for activation of the nuclear
mesenchymal stromal cells
e, Queen Mary Hospital, The
55 4769; fax: +852 2816 2187.In MM, the BMmicroenvironment plays an essential role in myelo-
ma plasma cell proliferation, migration, survival and drug resistance
[8]. Moreover, it has been suggested that the BM microenvironment
stimulated RANKL expression from BMSCs when co-cultured with mye-
loma cells [9,10]. However, whether the microenvironment is involved
in the expression of RANKL in myeloma cells remains unclear.
Promoter DNA methylation is characterized by the addition of a
methyl group to the carbon 5 position of cytosine ring in promoter-
associated CpG islands, which is associated with gene silencing [11].
However, DNAmethylation is dynamic and reversible. Moreover, recent
studies indicated that DNA methylation is involved in the regulation of
RANKL expression [12]. Herein, we study whether the microenviron-
ment may inﬂuence the RANKL expression in MM cells, and thereafter
the mechanisms involved.2. Material and methods
2.1. Cell culture
2.1.1. Human BMSCs
Bone marrow mononuclear cells from healthy bone marrow trans-
plantation donors were obtained with written informed consent
under approval of Institutional Review Board (TheHong Kong Universi-
ty and Hong Kong West Cluster Hospitals). Normal BMSCs were
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methods then expanded and characterized in vitro according to our pre-
vious published method [10].2.1.2. MM cell lines
Culture conditions of WL-2 and 8 other myeloma cell lines are de-
scribed in the supplemental material.Fig. 1. Promotermethylation and expression of RANKL. (A)M-/U-MSP shows that theWL-2myel
(lane 1), KMS-12-PE (lane 2), MOLP-8 (lane 3), NCI-H929 (lane 4), OCL-MY5 (lane 5), OPM-2 (l
template) control. (B)M-/U-MSP analysis of RANKL promotermethylation status inWL-2 cells (la
cells (lane 2). Methylated control (lane 3) and negative control (lane 4). (C) qRT-PCR analysis o
pression inWL-2 cells. (D) Transwell co-culture of WL-2 cells and BMSCs resulted in demethyla
culture of WL-2 cells and BMSCs; lane 3: positive control; lane 4: negative control (reagent blan2.1.3. Co-culture of MM and BMSCs
A serial co-culture experiment was used, 2 × 106/well WL-2 cells
were placed in a transwell insert (0.4 μm pore size; Coring Costar,
Cambridge, MA) to conﬂuent BMSCs (2 × 105/well), or added directly
to BMSCs. To separate the MM and BMSCs in contact co-culture, co-
cultures were harvested from myeloma cells using a positive immuno-
selection with anti-CD138 mAb (MACS, Miltenyi Biotec, Bergisch
Gladbach, Germany) at the end of culture period [13,14].oma cells (lane 9) andmethylated control [PC] (lane 10) are totally methylated, while JJN-3
ane 6), RPMI-8226 (lane 7), U266 (lane 8) are partially methylated. Lane 11 is negative (no
ne 1), and 1.5 μm5-AzadC treatment resulted in demethylation of RANKL promoter inWL-2
f the RANKL expression in WL-2 cells. 5-AzadC treatment led to re-expression of RANKL ex-
tion of RANKL promoter in WL-2 cells. M: marker; lane 1: WL-2 cells; lane 2: transwell co-
k). (E) RANKL expression inWL-2 cells after transwell or contact co-culture with BMSCs.
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trations of recombinant human TNFα (Sigma, St. Louis, Mo.) were
added to the culture medium of WL-2 cells.
To verify the effect of TNFα, WL-2 cells were pretreated for 20 min
in the presence of anti-TNFα monoclonal antibody (1 μg/ml, R&D
Systems, Minneapolis, MN) or anti-immunoglobulin G (IgG) control,
and these antibodies were maintained throughout the transwell co-
culture period.Fig. 2.Mechanism study of RANKL promoter demethylation inWL-2 after co-culturewith BMSC
GADD45a inWL-2 cells (lane 1), WL-2 cells transwell co-cultured with BMSCs (lane 2) andWL
usingWestern blot after treatment ofWL-2 cells with varying concentrations of recombinant T
nant TNFα protein with indicated concentration was determined by qRT-PCR. (D) miR-126 an
using stem-loop qRT-PCR analysis. (E) RANKL expression in WL-2 cells after transwell co-cul
and miR-140-3p expression in WL-2 cells after transwell co-culture with BMSCs in the prese
transwell co-culture with BMSCs in the presence of anti-TNFαmonoclonal antibody or IgG, rep3. Methylation-speciﬁc polymerase chain reaction and quantitative
bisulﬁte pyrosequencing
DNA was extracted from JJN-3, KMS-12-PE, MOLP-8, NCI-H929,
OCL-MY5, OPM-2, RPMI-8226, U266 and WL-2 myeloma cell lines by
standard method. Bisulﬁte conversion was performed using EpiTect
Bisulﬁte Kit (QIAGEN). Primers and condition of MSP and pyrosequenc-
ing are detailed in supplementary material.s. (A) Expression ofmolecules implicated inDNAdemethylation includingDNMT1, AID and
-2 cells in contact co-culture with BMSCs (lane 3). (B) DNMT1 expression was determined
NFα protein for 6 days. (C) RANKL expression inWL-2 cells after treatment with recombi-
d miR-140-3p expression in WL-2 cells after treatment with recombinant TNFα protein
ture with BMSCs in the presence of anti-TNFαmonoclonal antibody or IgG. (F) miR-126
nce of anti-TNFαmonoclonal antibody or IgG. (G) DNMT1 expression in WL-2 cells after
resentative Western blot result is shown.
1837L. Yuan et al. / Biochimica et Biophysica Acta 1843 (2014) 1834–18383.1. 5-Aza-2′-deoxycytidine (5-AzadC) treatment
WL-2 cells were seeded in six-well plates at a density of 1 × 106
cells/ml and cultured with 1.5 μM of 5-AzadC (Sigma-Aldrich, St.
Louis, MO) for 6 days.
3.1.1. Quantitative PCR
RNAwas isolated, reverse transcribed for quantitative real-time PCR
(qRT-PCR) of RANKL, miR126 and miR140-3p. GAPDH and SNORD48
were used as reference for RANKL and microRNA using the 2−ΔΔCt
method.
3.1.2. Western blot
Western blot was carried out as previously described using anti-
DNMT1, -GADD45a, -AID and β-actin antibody (Santa Cruz Biotechnolo-
gy, Santa Cruz, CA) [15].
4. Results and discussion
A previous study showed that methylation of the CpG island located
between−260 bp to +615 of the TSS correlated with RANKL expres-
sion [12], and hence studied herein.MSP showed completemethylation
of RANKL in WL-2 cells and positive control, and partial methylation in
JJN-3, KMS-12-PE, MOLP-8, NCI-H929, OCL-MY5, OPM-2, RPMI-8226
and U266. (Fig. 1A, MSP primer target on−48 to 107 bp). Furthermore,
complete methylation of RANKL promoter in WL-2 cells was associated
with undetectable RANKL expression determined by qRT-PCR (Fig. 1C).
Incubation of WL-2 cells with 1.5 μM of 5-AzadC resulted in demethyl-
ation of RANKL promoter as evidenced by emergence of the U-MSP sig-
nal (Fig. 1B), which was associated with re-expression of RANKL as
evidenced by qRT-PCR (Fig. 1C). Therefore, WL-2 cells were utilized to
explore the mechanisms of promoter DNA methylation regulating ex-
pression of RANKL in myeloma.
Using a transwell co-culture systemwithWL-2 cells and BMSCs, we
investigated whether the microenvironment affected RANKL promoter
methylation and expression in WL-2 cells. After 6 days of transwell
co-culture, partial demethylation of RANKL promoter occurred
(Fig. 1D), accompanied by upregulation of RANKL expression (Fig. 1E).
To see if contact co-culture might lead to additional upregulation of
RANKL, WL-2 cells were cultured with BMSCs in a contact co-culture
manner, which yielded RANKL expression comparable to that of
transwell co-culture (Fig. 1E). These results suggested that soluble fac-
tors in the microenvironment were primarily involved in RANKL pro-
moter demethylation and expression in WL-2 cells, which was not
enhanced by cell adhesion through contact co-culture.
DNA demethylation may reverse epigenetic silencing by promoter
DNA methylation. Recent studies revealed that demethylation of meth-
ylated CpG dinucleotides can be achieved by a passive or active process
[16]. Passive DNA demethylation is mediated by inhibition of DNMT1,
and hence unmethylated alleles are generated during cellular replica-
tion. On the other hand, active DNA demethylation of methylated CpG
dinucleotides is catalyzed by several enzymes [17] including GADD45a,
activation-induced deaminase (AID), ten–eleven translocation (TET)
and elongator complex protein 3 (ELP3). To explore the mechanism of
demethylation of the RANKL promoter in WL-2 cells, we determined
the passive and active demethylation related protein expression after
the transwell and contact co-culture of WL-2 with BMSCs. Our results
showed that levels of GADD45a and AID remained unaltered after
transwell or contact co-culture (Fig. 2A). By contrast, DNMT1 expression
was signiﬁcantly reduced in WL-2 cells after the transwell co-culture
with BMSCs for 6 days. However, contact co-culture of WL-2 cells and
BMSCs did not yield additional DNMT1 downregulation compared with
transwell co-culture (Fig. 2A). The expression of TET-1 isn't detected in
WL-2 cells and BMSCs (data not shown), and since ELP3 has been
shown to lead to active demethylation of zygotic paternal genomerather than gene-speciﬁc demethylation [18], ELP3 was not examined
in the present experiment.
The effect of transwell co-culture of WL-2 cells and BMSCs resulting
in downregulation of DNMT1 in WL-2 cells suggested a paracrine cyto-
kine mechanism. Of the cytokines secreted by myeloma BMSCs, a liter-
ature review showed that TNFα has been reported to be involved in
DNA demethylation [19]. To verify the role of TNFα in RANKL demethyl-
ation and re-expression in myeloma cells, WL-2 myeloma cells were
treated with recombinant TNFα. A previous study showed that theme-
dian concentration of TNFα in the BM plasma of myeloma patients was
about 0.35 ng/ml, and the supernatant of myeloma cells co-cultured
with BMSCs ranged from 0.118 to 0.152 ng/ml [20]. Therefore, WL-2
cells were cultured with recombinant TNFα protein at concentrations
between 0.1 and 1.0 ng/ml, which led to downregulation of DNMT1 ex-
pression (Fig. 2B) and upregulation of RANKL expression (Fig. 2C) in
WL-2 cells after 6 day treatment.
On the other hand, miR-140-3p andmiR-126 [21,22], which are reg-
ulated by TNFα, have been shown by luciferase assays to directly target
and repress DNMT1 translation [23,24]. Consistent with these data, we
showed that miR-140-3p and miR-126 expression was upregulated by
treatment of WL-2 cells with recombinant TNFα (Fig. 2D). As previous
studies have shown secretion of TNFα in the supernatant of transwell-
coculture of myeloma cells with BMSCs [19], anti-TNFα antibody was
added to the transwell co-culture of WL-2 with BMSCs, which partially
abrogated the co-culture-induced RANKL expression (Fig. 2E) and up-
regulation of miR-140-3p and miR-126 (Fig. 2F), and offset DNMT1
downregulation (Fig. 2G) inWL-2 cells. Furthermore, our pyrosequenc-
ing results showed the anti-TNFα antibody could attenuate the co-
culture induced demethylation in WL-2 cells (Fig. S1). Taken together,
the above results testiﬁed to the role of TNFα in the induction of de-
methylation and re-expression of RANKL inmyeloma cells via upregula-
tion ofmiR-126 and -140-3p,whichmay lead to translational inhibition,
and hence downregulation, of DNMT1.
In conclusion, in the BM microenvironment, RANKL expression in
myeloma cells is mediated by RANKL promoter demethylation induced
by downregulation of DNMT1, which is associated with upregulation
of miR-126 and -140-3p. TNFα plays a pivotal role in this paracrine
mechanism.
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